%0 Journal Article
%T Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
%A Armin Haupt
%A Gerard Joberty
%A Marcus Bantscheff
%A Holger Fr£¿hlich
%A Henning Stehr
%A Michal R Schweiger
%A Axel Fischer
%A Martin Kerick
%A Stefan T Boerno
%A Andreas Dahl
%A Michael Lappe
%A Hans Lehrach
%A Cayetano Gonzalez
%A Gerard Drewes
%A Bodo MH Lange
%J BMC Cancer
%D 2012
%I BioMed Central
%R 10.1186/1471-2407-12-38
%X We quantitatively profiled the effects of Hsp90 inhibition by geldanamycin on the kinome of one primary (Hs68) and three tumour cell lines (SW480, U2OS, A549) by affinity proteomics based on immobilized broad spectrum kinase inhibitors ("kinobeads"). To identify affected pathways we used the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway classification. We combined Hsp90 and proteasome inhibition to identify Hsp90 substrates in Hs68 and SW480 cells. The mutational status of kinases from the used cell lines was determined using next-generation sequencing. A mutation of Hsp90 candidate client RIPK2 was mapped onto its structure.We measured relative abundances of > 140 protein kinases from the four cell lines in response to geldanamycin treatment and identified many new potential Hsp90 substrates. These kinases represent diverse families and cellular functions, with a strong representation of pathways involved in tumour progression like the BMP, MAPK and TGF-beta signalling cascades. Co-treatment with the proteasome inhibitor MG132 enabled us to classify 64 kinases as true Hsp90 clients. Finally, mutations in 7 kinases correlate with an altered response to Hsp90 inhibition. Structural modelling of the candidate client RIPK2 suggests an impact of the mutation on a proposed Hsp90 binding domain.We propose a high confidence list of Hsp90 kinase clients, which provides new opportunities for targeted and combinatorial cancer treatment and diagnostic applications.Hsp90 is part of the molecular chaperones family responsible for ATP-dependent folding and activation of proteins. Unlike other chaperones, Hsp90 is in most cases not involved in the de novo folding of proteins but stabilizes folded conformations and regulates protein degradation [1]. Another important difference is the selectivity of Hsp90 for its substrates, which therefore are called clients. Most of these client proteins are involved in signal transduction, including kinases, nuclear hormone receptors an
%U http://www.biomedcentral.com/1471-2407/12/38